Data / Drug companies / Gonadotropin Releasing Hormone Receptor Agonist
Gonadotropin Releasing Hormone Receptor Agonist drugs: 5 drugs from 8 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Gonadotropin Releasing Hormone Receptor Agonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 17 products in this class from 8 companies, covering 5 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on October 31, 2026.
The request: Get every company that lists a Gonadotropin Releasing Hormone Receptor Agonist drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 8Companies
- 17Products
- 5Drugs by generic name
Drugs in the Gonadotropin Releasing Hormone Receptor Agonist class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Leuprolide acetate | 10 | 16 |
| Leuprolide | 3 | 2 |
| Goserelin | 2 | 1 |
| Histrelin acetate | 1 | 1 |
| Nafarelin acetate | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Tolmar Inc. | 5 | injection, suspension, extended release | New drug applications (NDA) | January 11, 2024 |
| Uronova Pharmaceuticals, Inc. | 4 | injection, suspension, extended release | Authorized generics (NDA) | December 15, 2025 |
| Accord BioPharma Inc. | 2 | injection, emulsion | New drug applications (NDA) | May 19, 2025 |
| TerSera Therapeutics LLC | 2 | implant | New drug applications (NDA) | March 31, 2018 |
| Endo USA, Inc. | 1 | implant | New drug applications (NDA) | May 31, 2007 |
| Foresee Pharmaceuticals Co., Ltd. | 1 | injection, emulsion | New drug applications (NDA) | October 31, 2026 |
| Par Health USA, LLC | 1 | injection | Generic drugs (ANDA) | June 30, 2026 |
| Pfizer Laboratories Div Pfizer Inc | 1 | spray, metered | New drug applications (NDA) | February 13, 1990 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, suspension, extended release | 9 | 52.9% |
| Implant | 3 | 17.6% |
| Injection, emulsion | 3 | 17.6% |
| Injection | 1 | 5.9% |
| Spray, metered | 1 | 5.9% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.